MEDMEDIFAST INCvs its industry peers
A metric-by-metric comparison of MEDIFAST INC against SIC 2090 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEDEsta | $134M#3 | — | 0.7x#1 | 0.3x#2 | -36.0%#6 | -1050.0%#6 | -3.7%#6 | -9.7%#6 | — | 4#1 | -15.1%#1 | 0.1%#4 |
| JVA | $24M#4 | 5.1x#2 | 0.8x#3 | 0.3x#1 | 22.6%#2 | -36.7%#4 | 2.2%#4 | 4.5%#4 | — | — | -15.1%#2 | 1.6%#3 |
| MKC | $13.5B#2 | 8.3x#3 | 1.9x#4 | 2.0x#3 | 1.7%#4 | 0.1%#2 | 15.7%#2 | 11.3%#2 | 7.3%#2 | — | -22.5%#4 | 3.6%#1 |
| MKC.V | $14.2B#1 | 8.8x#4 | 2.0x#5 | 2.1x#4 | 1.7%#4 | 0.1%#2 | 15.7%#2 | 11.3%#2 | 7.3%#2 | — | -21.1%#3 | 3.4%#2 |
| TWG | $20M#5 | 0.1x#1 | 0.7x#2 | 2.2x#5 | 92.3%#1 | 258.0%#1 | 41.6%#1 | 11.5%#1 | 12.0%#1 | — | -93.5%#5 | — |
| UTZ | — | — | — | — | 2.1%#3 | -95.0%#5 | 1.4%#5 | 0.1%#5 | 1.3%#4 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2090). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice